Schultheiss H P, Berg P A, Klingenberg M
Clin Exp Immunol. 1984 Dec;58(3):596-602.
Sera from 13 patients with proven primary biliary cirrhosis (PBC) were studied for the capacity to bind to the adenine nucleotide translocator (ANT) isolated from heart, kidney and liver mitochondria. Antibodies against the ANT from liver were detected in the serum of all PBC patients, while 10 of 13 sera were negative when tested with the ANT from heart. None of the sera showed a significant binding to the ANT from kidney. The specific binding and the organ specificity of the autoantibodies against the ANT from liver were also confirmed by immunoabsorption studies on the isolated proteins. To distinguish between antibody titre and antibody activity, we measured the ability of the antisera to inhibit the adenine nucleotide transport across inner mitochondrial membrane using isolated mitochondria from heart, kidney and liver. Six of 13 patient sera tested inhibited the adenine nucleotide transport from liver mitochondria, however, none of the sera inhibited the transport from heart or kidney mitochondria again indicating the organ specificity of the antigen and the autoantibodies.
对13例经证实患有原发性胆汁性肝硬化(PBC)患者的血清进行了研究,以检测其与从心脏、肾脏和肝脏线粒体中分离出的腺嘌呤核苷酸转位酶(ANT)的结合能力。所有PBC患者血清中均检测到针对肝脏ANT的抗体,而用心脏来源的ANT检测时,13份血清中有10份呈阴性。所有血清与肾脏来源的ANT均未显示出明显结合。针对肝脏ANT的自身抗体的特异性结合和器官特异性也通过对分离蛋白的免疫吸收研究得到了证实。为了区分抗体滴度和抗体活性,我们使用从心脏、肾脏和肝脏分离的线粒体,测量了抗血清抑制腺嘌呤核苷酸跨线粒体内膜转运的能力。13份受试患者血清中有6份抑制了肝脏线粒体的腺嘌呤核苷酸转运,然而,没有一份血清抑制心脏或肾脏线粒体的转运,这再次表明了抗原和自身抗体的器官特异性。